Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2024 | FDA-approved anti-CD20 therapies for the treatment of MS: similarities and differences

Barry Singer, MD, The MS Center for Innovations in Care, St. Louis, MO, gives an overview of the anti-CD20 therapies that are currently FDA-approved to treat multiple sclerosis (MS) in the USA. These therapies disrupt the B-cell-mediated component of the immune response, leading to a reduction in autoimmune activity and taregting the progression of MS. Ocrelizumab, administered intravenously twice yearly, is approved for relapsing forms of MS as well as early primary progressive MS. Ofatumumab offers the convenience of subcutaneous self-administration at home. The latest addition, ublituximab, features a quicker 1-hour infusion time. This interview took place during the annual ACTRIMS Forum 2024.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.